Form 4: Zoetis CEO Kristin Peck Receives Equity Awards
Insider Transaction Report
Zoetis Inc. CEO and Director Kristin C. Peck was granted 28,072 Restricted Stock Units and 111,060 Stock Options under the company's equity incentive plan.
Summary
- Kristin C. Peck, Chief Executive Officer and Director of Zoetis Inc., received new equity awards.
- The awards, granted on February 18, 2026, include 28,072 Restricted Stock Units (RSUs) and 111,060 Stock Options.
- These grants were made pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
- The 28,072 RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the grant date (February 18, 2026), contingent on continued service.
- The 111,060 newly granted stock options have an exercise price of $129.13 and will vest in three equal annual installments on the first, second, and third anniversaries of the grant date (February 18, 2026), expiring on the tenth anniversary of the grant.
- The filing also details previously granted, unvested RSUs and stock options held by Ms. Peck from prior years, including grants from February 6, 2024, February 19, 2025, and various dates between 2017 and 2023.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term shareholder value, without indicating any immediate operational changes or financial performance shifts.
Positives
- The grant of equity awards aligns the interests of CEO Kristin C. Peck with those of shareholders, incentivizing long-term company performance.
- The awards are part of a structured equity incentive plan, indicating a standard and transparent approach to executive compensation.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-arranged and non-opportunistic trading strategy.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that equity grants to top executives like Kristin C. Peck are a standard practice across the pharmaceutical and animal health industries. These awards are designed to align executive incentives with long-term shareholder value creation, a common strategy for retaining key talent and driving strategic objectives in competitive sectors.
Comparison to Industry Standards
- The structure of these equity awards, including a mix of Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules, is consistent with executive compensation practices observed at peer companies in the animal health sector, such as Elanco Animal Health (ELAN) and IDEXX Laboratories (IDXX).
- The use of the company's 2013 Equity and Incentive Plan for these grants is a common governance practice, ensuring awards are made under a shareholder-approved framework.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Plan Utilization | Awards granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan. | 2026-02-18 | Reinforces the company's established framework for executive compensation and aligns management incentives with shareholder interests. |
| Rule 10b5-1 Plan | Transaction made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | NA | Indicates a pre-arranged trading plan, reducing concerns about opportunistic insider trading and providing a legal defense against such claims. |
Stakeholder Impact
- Shareholders: The equity grants are designed to align the CEO's long-term interests with shareholder value creation, potentially leading to improved company performance.
- Employees: The equity incentive plan is a key component of executive compensation, which can influence overall compensation philosophy and talent retention strategies within the company.
Next Steps
- Vesting of the newly granted Restricted Stock Units and Stock Options will occur in three annual installments starting February 18, 2027, subject to continued service.
- Previously granted equity awards will continue to vest according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 2017-02-14 | Grant date for 32,634 stock options with an exercise price of $55.02, which vested on the third anniversary. |
| 2018-02-13 | Grant date for 24,642 stock options with an exercise price of $73.24, which vested on the third anniversary. |
| 2019-02-12 | Grant date for 20,661 stock options with an exercise price of $87.51, which vested on the third anniversary. |
| 2020-02-11 | Grant date for 55,866 stock options with an exercise price of $144.03, which vested on the third anniversary. |
| 2021-02-10 | Grant date for 61,078 stock options with an exercise price of $160.62, which vested on the third anniversary. |
| 2022-02-08 | Grant date for 54,751 stock options with an exercise price of $201.30, which vested on the third anniversary. |
| 2023-02-08 | Grant date for 67,148 stock options with an exercise price of $162.07, with one-third vesting on the first, second, and third anniversaries. |
| 2024-02-06 | Grant date for 5,556 Restricted Stock Units and 62,500 stock options with an exercise price of $196.14, with one-third vesting on the first, second, and third anniversaries. |
| 2025-02-19 | Grant date for 22,062.8977 Restricted Stock Units and 84,711 stock options with an exercise price of $156.64, with one-third vesting on the first, second, and third anniversaries. |
| 2026-02-18 | Grant date for 28,072 Restricted Stock Units and 111,060 stock options with an exercise price of $129.13, with one-third vesting on the first, second, and third anniversaries. |
| 2026-02-19 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThis Form 4 filing reports routine equity compensation grants to the CEO, which is an expected part of executive remuneration. While it aligns management incentives with shareholder interests, it does not present new information that would fundamentally alter the investment thesis for Zoetis Inc. Therefore, a 'hold' recommendation is appropriate as it confirms ongoing governance practices without providing a catalyst for a significant re-evaluation of the stock.
Keywords
Zoetis, ZTS, Kristin Peck, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Corporate Governance, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.